Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease

Human and Experimental Toxicology

Volumn 25, Issue 7, 2006, Pages 361-368

  Ahmad, Muzamil ^a,b   Yousuf, Seema ^a   Khan, M Badruzzaman ^a   Ahmad, Abdullah Shafique ^a,b   Saleem, Sofiyan ^a,b   Hoda, Md Nasrul ^a   Islam, Fakhrul ^a,b  

^a HAMDARD UNIVERSITY   (India)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; Anti oxidant; Delphinium denudatum; Herbal drugs; Neuroprotection; Oxidative stress

Indexed keywords

ASCORBIC ACID; CATALASE; CATECHOLAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTATHIONE; OXIDOPAMINE; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DELPHINIUM DENUDATUM; DOSE RESPONSE; ENZYME ACTIVITY; LARKSPUR; LIPID PEROXIDATION; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; CATALASE; DELPHINIUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; LIPID PEROXIDATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PLANT EXTRACTS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; DELPHINIUM; DELPHINIUM DENUDATUM;

EID: 33746519193     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327106ht635oa     Document Type: Article

References (40)

1. Hussain SM. Makhza-ul-advia, Volume I. Matba Munshi Nawal Kishore, 1875; 370-73. (Urdu translation by Moulvi Noor Karim)
2. Bhatnagar SS. The wealth of India. CSIR, 1952: 30.
3. Said HM. Hamdard pharmacopoeia of eastern medicine. Hamdard National Foundation, Times Press, 1970: 49.
4. Raza M, Shaheen F, Choudary MI, Sombati S, Rafia A, Suria A, et al. Anticonvulsant activities of ethanolic extract and aqueous fraction isolated from Delphinium denudatum. J Ethnopharmacol 2001; 78: 73-78.
5. Zafar S, Ahmad MA, Siddiqui TA. Protective role of Delphinium denudatum (Jadwar) against morphine induced tolerance and dependence in mice. J Ethnopharmacol 2001; 78: 95-98.
6. Ahmad G, Yusuf AKM, Khan NA, Tajuddin. The antistress activity of a gem-containing Unani formulation against diverse stressors. J Ethnopharmacol 1998; 59: 187-93.
7. Siddiqui R, Kazmi SU, Shekhani S. Proceedings of the Ninetieth Annual Meeting of the American Society for Microbiology, Anaheim, CA. 1990: 13-17.
8. Khan AB. The radioprotectant effect of aqueous extract of Delphinium denudatum Wall against radiation-induced changes in rat myocardium. J Mol Cell Cardiol 1989; 21: 171.
9. Khan AB, Taiyab HM. Effect of 'Jadwar' Delphinium denudatum Wall on experimental liver damage in rats. Indian J Pharmaceut Sci 1981; 43: 120-22.
10. Singh N, Chopra KL. Diterpene alkaloids. Isolation and study of two new alkaloids. J Pharm Pharmacol 1962; 14: 288-93.
11. Pelletier SW, Keith LH, Parthasarathy PC. The struc-tures of condelphine, isotalatizidine, and talatizidine. J Am Chem Soc 1967; 89: 4146-57.
12. Atta-ur-Rahman, Nasreen A, Akhtar F, Shekhani MS, Clardy J, Parvez M, et al. Antifungal diterpenoid alkaloids from Delphinium denudatum. J Nat Prod 1997; 60: 472-74.
13. Dobelis P, Madl JE, Pfister JA, Manners GD, Walrond JP. Effects of Delphinium alkaloids on neuromuscular transmission. J Pharmacol Exp Therapeut 1999; 291: 538-46.
14. von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004; 73: 151-77.
15. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tiss Res 2004; 318: 215-24.
16. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 1992; 29: 699-701.
17. Kumar R, Agarwal AK, Seth PK. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995; 64: 1703-707.
18. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990; 170: 1049-55.
19. Oleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992; 58: 786-89.
20. Paxinos G, Watson C. The rat brain stereotaxic coordinates. Academic Press, 1982.
21. Utley HC, Bernheim F, Hochslein P. Effect of sulfahydryl reagent on peroxidation in microsome. Arch Biochem Biophys 1967; 260: 521-31.
22. Jollow DJ, Mitchell JR, Zampagloine N, Gillete JR. Bromobenzene-induced liver necrosis: protective role of glutathione and evidence for 3, 4 bromobenzeneoxide as the hepatotoxic intermediate. Pharmacology 1974; 11: 151-69.
23. Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Ann Biochem 1971; 44: 276-87.
24. Shah ZA, Sharma P, Vohora SB. Ginkgo biloba normalises stress-elevated alterations in brain catecholamines, serotonin and plasma corticosterone levels. Eur Neuropsychopharmacol 2003; 13: 321-25.
25. Coliborne A. Catalase activity. In Green Wald RA ed. CRC handbook of methods for oxygen radical research. CRC Press, 1985: 283-84.
26. DeVito MJ, Wagner GC. Methamphetamine induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989; 28: 1145-50.
27. Zafar KS, Sayeed I, Siddiqui A, Ahmad M, Salim S, Islam F. Dose-dependent protective effect of selenium in partial lesion model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Neurochem 2003a; 84: 438-46.
28. Agrawal AK, Hussin R, Raghubir R, Agrawal AK, Seth PK. Neurobehavioral, neurochemical and electrophysiological studies in 6-hydroxydopamine lesioned and transplanted rats. Int J Dev Neurosci 1995; 13: 105-11.
29. Lowry OH, Rosenbrough NJ, Far AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
30. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, et al. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol 2005a; 24: 137-47.
31. Zafar KS, Siddiqui A, Sayeed I, Ahmad M, Salim S, Islam F. Protective effect of adenosine in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Chem Neuroanat 2003b; 26: 143-51.
32. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, et al. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced Parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 2005b; 93: 94-104.
33. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. J Free Rad Biol Med 1990; 8: 583-99.
34. Fridovich I. Superoxide dismutases: an adaptation to a paramagnetic gas. J Biol Chem 1975; 264: 19328-333.
35. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47: 412-26.
36. 1 receptor stimulation. J Neurosci 1990; 10: 2318-29.
37. Carman LS, Gage FH, Shults CW. Partial lesion of the subtantia nigra: relation between extent of lesion and rotation behavior. Brain Res 1991; 553: 275-83.
38. Hudson JL, Horny CG, Stromberg I, Brock S, Claton J, Masserano J, et al. Correlation of apomorphine and amphetamine induced turning with nigrastriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993; 626: 167-74.
39. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesion of meso-striatal dopamine neurons and their sequelae. Prog Neurobiol 1996; 49: 215-66.
40. Brown DF, Dababo MA, Bigio MH, Riser RC, Eagan KP, Hladik CL, et al. Neuropathologic evidence that the Lewy body variant of Alzheimer's disease represents co existence of Alzheimer's disease and idiopathic Parkinson's disease. J Neuropathol Exp Neurol 1998; 57: 39-16.